{"prompt": "['PREDM', 'Page 4', 'PREDM: An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic', 'Adult Survivors of Childhood Cancer', 'weight/anthropometric measures, physical activity and frailty in adult survivors of', 'childhood cancer who have prediabetes. The objective of this study is to provide initial', 'evidence for feasibility, safety and efficacy in a pilot, open-label setting. If successful,', 'these results will provide necessary preliminary data for a randomized, multi-arm phase', '2b trial of efficacy.', 'Sample Size: We anticipate enrolling approximately 41 participants.', 'Data Management: The study team consisting of the study PI, study coordinator,', 'protocol nurse, and the study statistician will be responsible for data management and', 'monitoring, including implementation of stopping rules for feasibility and safety.', 'Statistical analyses will be performed by the Department of Epidemiology and Cancer', \"Control and the Biostatistics Department at St. Jude Children's Research Hospital.\", 'Human Subjects: The risk to subjects will be related to the toxicity of metformin', 'extended release. Metformin is a biguanide class oral hypoglycemic agent that is FDA-', 'approved to improve glycemic control in adults and pediatric patients 10 years of age and', 'older with type 2 diabetes mellitus. It has been widely utilized with safety and efficacy', \"data in prediabetic adults, outside of it's FDA-approved indication. The expected side\", 'effects of metformin are gastrointestinal symptoms (diarrhea, nausea, flatulence, bloating).', 'Participants will be informed of this during informed consent discussion and adverse', 'events will be monitored, reported and managed according to good medical practice.', 'Commercially available metformin extended release will be purchased and supplied as 500', 'mg tables at a dose of 500 mg on days 1-14, escalated to 1000 mg day 15 through study', 'end (week 24).', 'Metformin extended release is associated with fewer gastrointestinal side effects,', 'especially when the dose is titrated, as planned in our study. Metformin may cause lactic', 'acidosis in extreme clinical scenarios including overdose and, therefore, patients with risk', 'factors for lactic acidosis including severe chronic kidney disease, hepatic impairment or', 'acute heart failure will be excluded.', 'The primary features of the lifestyle change program include a curriculum focused on diet', 'and exercise goals using behavioral strategies and led by a lifestyle coach. Unique physical', 'activity limitations of survivors, including frailty, may be a barrier to incorporating', 'activity goals to meet the recommended 150 min/week, however, as no specific exercise or', 'dietary restrictions are prescribed we do not anticipate adverse events related to the', 'lifestyle component of the study.', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approRB date: 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 5', '1.0 OBJECTIVES', '7', '1.1 Primary Objective', '7', '1.2 Secondary Objectives', '7', '1.3 Exploratory Objectives', '7', '2.0 BACKGROUND AND RATIONALE', '8', '2.1 Background', '8', '2.2 Rationale', '10', '3.0 PARTICIPANT ELIGIBILITY CRITERIA AND STUDY ENROLLMENT', '13', '3.1 Inclusion Criteria', '13', '3.2 Exclusion Criteria', '13', '3.3 Research Participant Recruitment and Screening', '17', '3.4 Enrollment on Study at St. Jude', '18', '3.5 Procedures for Identifying and Randomizing Research Participants', '18', '3.6 Compensation', '19', '4.0 DESIGN AND METHODS', '19', '4.1 Design and Study Overview', '19', '4.2 Definition and assessment of outcome measures', '20', '5.0 TREATMENT PLAN', '25', '5.1 Treatment', '25', '5.2 Dose Modifications', '26', '5.3 Definitions of Toxicity', '29', '5.4 Concomitant Therapy', '30', '5.5 Supportive Care', '31', '6.0 DRUG INFORMATION', '31', '6.1 Drug Distribution', '33', '7.0 REQUIRED EVALUATIONS, TESTS, AND OBSERVATIONS', '33', '7.1 Screening Evaluations', '34', '7.2 Evaluations During Therapy', '35', '7.3 Response Evaluations', '36', '7.4 Off-Study Evaluations', '36', '7.5 Long-Term Follow-up Evaluations', '36', '8.0 EVALUATION CRITERIA', '36', '8.1 Response Criteria', '36', '8.2 Toxicity Evaluation Criteria', '36', '8.3 Subject Compliance Monitoring', '37', '9.0 OFF STUDY AND OFF THERAPY CRITERIA', '37', '9.1 Off study criteria', '37', '9.2 Off therapy criteria', '38', '10.0 SAFETY AND ADVERSE EVENT REPORTING REQUIREMENTS', '38', '10.1 Adverse Events (AEs)', '38', '10.2 Definitions', '38', '10.3 Handling of Adverse Events (AEs) and Deaths', '39', '10.4 Emergency Unblinding', '40', '11.0 DATA COLLECTION, STUDY MONITORING, AND CONFIDENTIALITY', '40', '11.1 Data Collection', '40', '11.2 Study Monitoring', '41', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}